Peter Lawyer
Senior Advisor
Minneapolis
Pete Lawyer is a core member of Boston Consulting Group’s Health Care and Corporate Finance & Strategy practices. He works with clients on innovation, growth, operational excellence, competitive strategy issues, and M&A. Pete is the founder of BCG’s medtech sector and opened the firm’s Minneapolis office in 2007.
Since joining BCG in 1989, Pete has worked in the firm's Chicago and Tokyo offices as well as Minneapolis. He works principally on core competitive strategy and growth topics, relying on internal innovation and restructuring as well as M&A to help BCG's global clients achieve their goals.
Before joining BCG, Pete was a reporter for the Wall Street Journal Europe and a commercial banker for First Bank System (now US Bank).
As countries begin to lift restrictions on social interaction, effective deployment of contact tracing will be a critical weapon in the battle to contain COVID-19. But it won’t succeed without privacy safeguards and the right incentives for adoption.
A recent analysis shows disturbing variations in the use of a key diagnostic for lung cancer patients. Adopting new protocols and tools can lead to better care.
Consolidation won’t move the needle on health care value unless the newly combined insurers use some of the savings to invest in and extend their clinical capabilities.
Consolidation won’t move the needle on health care value unless the newly combined insurers use some of the savings to invest in and extend their clinical capabilities.
Many product manufacturers find it difficult to add even basic services, let alone sophisticated offerings that deliver value. Insights distilled from service pros show how to profitably tackle the challenge.
A new focus on value is fundamentally changing the terms of competition in the health care market. The winners will be organizations that compete on outcomes.
Targeting better health outcomes is the key to sustainable health reform—both to improve the quality of care and to curb excess health-care spending.
Which countries are positioned best to adopt value-based health care? BCG assessed the health systems of 12 developed-world countries to find out.
Value-based health care represents a major challenge to the pharmaceutical sector. Here’s how pharma companies can turn a potential threat into a promising opportunity.
High-quality observational data are the foundation of value-based health care. For an example, consider the recently established National Cancer Intelligence Network in the U.K.
